Xanomeline and Trospium: Potential substitute for conventional antipsychotics
Dear Madam, Schizophrenia is a chronic mental illness with a global prevalence of 24 million people (1). With paucity of researches mounting the exact prevalence of schizophrenia in Pakistan, the treatment of this illness becomes even harder to combat. This condition is typically managed with antip...
Main Authors: | Nashit Irfan Aziz, Nida Rahman Khan, Muhammad Yusuf Hafiz |
---|---|
Format: | Article |
Language: | English |
Published: |
Pakistan Medical Association
2022-08-01
|
Series: | Journal of the Pakistan Medical Association |
Online Access: | https://www.ojs.jpma.org.pk/index.php/public_html/article/view/5732 |
Similar Items
-
Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
by: Kidambi N, et al.
Published: (2023-05-01) -
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
by: Colin Sauder, et al.
Published: (2022-11-01) -
Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.
by: Marianne K O Grant, et al.
Published: (2010-12-01) -
Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR
by: Wessel A. C. Burger, et al.
Published: (2023-09-01) -
Novel Xanomeline-Containing Bitopic Ligands of Muscarinic Acetylcholine Receptors: Design, Synthesis and FRET Investigation
by: Carlo Matera, et al.
Published: (2023-03-01)